David Martin PhD
Stock Analyst at Bloom Burton
(4.78)
# 633
Out of 4,698 analysts
236
Total ratings
53.8%
Success rate
19.8%
Average return
Main Sectors:
Stocks Rated by David Martin PhD
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintained: Buy | $36 → $37 | $28.77 | +28.61% | 14 | Aug 27, 2026 | |
| TSXV: RX BioSyent Inc. | Maintained: Buy | $18.00 | $15.50 | +16.13% | 15 | Aug 25, 2026 | |
| AUPH Aurinia Pharmaceuticals | Upgraded: Buy | $15 → $21 | $16.57 | +26.74% | 35 | Aug 20, 2026 | |
| TSX: MBX Microbix Biosystems Inc. | Maintained: Buy | $0.40 | $0.31 | +29.03% | 14 | Aug 14, 2026 | |
| TSX: HLS HLS Therapeutics Inc. | Maintained: Buy | $12.00 | $3.69 | +225.20% | 51 | Aug 13, 2026 | |
| TSX: APTX Apotex Health Corp. | Maintained: Buy | $40.00 | $33.19 | +20.52% | 3 | Aug 13, 2026 | |
| TSX: MDP Medexus Pharmaceuticals Inc. | Maintained: Buy | $6.00 → $6.50 | $5.17 | +25.73% | 14 | Aug 12, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Maintained: Buy | $12.00 | $9.66 | +24.22% | 29 | Aug 7, 2026 | |
| ASX: PYC PYC Therapeutics Limited | Maintained: Buy | $5.00 | $2.07 | +141.55% | 4 | Aug 5, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $19.39 | $10.05 | +92.98% | 6 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5.00 | $3.24 | +54.32% | 12 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $47 | $13.02 | +260.98% | 8 | Jul 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $57 → $74 | $60.56 | +22.19% | 8 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8.31 → $4.00 | $0.44 | +819.54% | 11 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $10.61 | -15.17% | 6 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $24.02 | -40.80% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20.20 → $19.00 | $17.93 | n/a | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $1.00 | $0.15 | n/a | 2 | Jul 6, 2025 |
Zymeworks
Aug 27, 2026
Maintained: Buy
Price Target: $36 → $37
Current: $28.77
Upside: +28.61%
BioSyent Inc.
Aug 25, 2026
Maintained: Buy
Price Target: $18.00
Current: $15.50
Upside: +16.13%
Aurinia Pharmaceuticals
Aug 20, 2026
Upgraded: Buy
Price Target: $15 → $21
Current: $16.57
Upside: +26.74%
Microbix Biosystems Inc.
Aug 14, 2026
Maintained: Buy
Price Target: $0.40
Current: $0.31
Upside: +29.03%
HLS Therapeutics Inc.
Aug 13, 2026
Maintained: Buy
Price Target: $12.00
Current: $3.69
Upside: +225.20%
Apotex Health Corp.
Aug 13, 2026
Maintained: Buy
Price Target: $40.00
Current: $33.19
Upside: +20.52%
Medexus Pharmaceuticals Inc.
Aug 12, 2026
Maintained: Buy
Price Target: $6.00 → $6.50
Current: $5.17
Upside: +25.73%
Knight Therapeutics Inc.
Aug 7, 2026
Maintained: Buy
Price Target: $12.00
Current: $9.66
Upside: +24.22%
PYC Therapeutics Limited
Aug 5, 2026
Maintained: Buy
Price Target: $5.00
Current: $2.07
Upside: +141.55%
Eupraxia Pharmaceuticals Inc.
Aug 3, 2026
Maintained: Buy
Price Target: $19.39
Current: $10.05
Upside: +92.98%
Jul 31, 2026
Maintained: Buy
Price Target: $5.00
Current: $3.24
Upside: +54.32%
Jul 21, 2026
Maintained: Buy
Price Target: $47
Current: $13.02
Upside: +260.98%
Mar 9, 2026
Maintained: Buy
Price Target: $57 → $74
Current: $60.56
Upside: +22.19%
Dec 11, 2025
Maintained: Buy
Price Target: $8.31 → $4.00
Current: $0.44
Upside: +819.54%
Nov 19, 2025
Maintained: Buy
Price Target: $9
Current: $10.61
Upside: -15.17%
Oct 21, 2025
Maintained: Buy
Price Target: $14
Current: $24.02
Upside: -40.80%
Jul 18, 2025
Maintained: Buy
Price Target: $20.20 → $19.00
Current: $17.93
Upside: n/a
Jul 6, 2025
Initiated Coverage: Buy
Price Target: $1.00
Current: $0.15
Upside: n/a